The effect of potassium citrate and terpene combination for stone-free rate and ureteral stent-induced irritation symptoms after retrograde intrarenal surgery using dusting technique

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0011989

Enrollment

600

Registered

2026-05-15

Start date

2022-05-20

Completion date

Unknown

Last updated

2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Patients participating in this study will undergo conventional retrograde intrarenal surgery using a flexible ureteroscope. A minimal amount of stone material will be collected for stone compos

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Patients with renal stones smaller than 2 cm who are scheduled to undergo retrograde intrarenal surgery using a flexible ureteroscope. - Adult male or female patients aged 19 years or older who understand the contents of the informed consent form and are willing to participate in and continue the study.

Exclusion criteria

Exclusion criteria: Participants will be excluded from this clinical study if any of the following criteria are met: -Patients deemed unsuitable for participation in the study at the discretion of the investigator. -Patients who do not provide informed consent. -Patients with concomitant genitourinary malignancy. -Patients who undergo bilateral procedures or surgery for urinary stone disease. -Patients who are pregnant or breastfeeding. -Patients with ureteral disease, such as ureteral stricture. -Patients with a history of pelvic surgery or radiation therapy. -Patients with a history of adverse reactions or hypersensitivity to Urocitra-K or Rowatinex. -Patients with chronic kidney disease, defined as an estimated glomerular filtration rate 5.4 mmol/L, or a history of hyperkalemia. -Patients currently taking potassium-sparing diuretics, including triamterene, spironolactone, or amiloride. -Patients with chronic renal failure. -Patients with severe myocardial injury or heart failure. -Patients with uncontrolled diabetes mellitus. -Patients with acute dehydration. -Patients who continuously engage in strenuous exercise. -Patients with adrenal insufficiency. -Patients with extensive tissue breakdown. -Patients with gastrointestinal motility disorders, including delayed gastric emptying, esophageal stricture, gastrointestinal obstruction or stricture symptoms, or use of anticholinergic agents. -Patients with gastric ulcer. -Patients in whom the surgery is terminated without complete fragmentation of the stone. -Patients with preoperative urine pH >7.0. -Patients whose previous stone composition analysis confirmed infection stones, such as struvite stones. -Patients at high risk of adverse reactions to Urocitra-K or Rowatinex, or those in whom administration of either medication is contraindicated.

Design outcomes

Primary

Measure	Time frame
stone-free rate	—

Secondary

Measure	Time frame
ureteral stent related symptom	—

Countries

Korea, Republic of

Contacts

Public ContactJun-Koo Kang

Kyungpook National University Hospital

kangjk0082@naver.com+82-53-200-5843

Outcome results